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Summary
 
Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell sur-
face expression is induced under inflammatory conditions. It has been shown previously to par-
ticipate in lymphocyte recirculation by mediating the binding of lymphocytes to peripheral
lymph node vascular endothelial cells in an L-selectin–independent fashion. We report here
that the VAP-1 cDNA encodes a type II transmembrane protein of 84.6 kD with a single
transmembrane domain located at the NH
 
2
 
-terminal end of the molecule and six potential
 
N
 
-glycosylation sites in the extracellular domain. In vivo, the protein exists predominantly as a
homodimer of 170–180 kD. Ax endothelial cells transfected with a VAP-1 cDNA express
VAP-1 on their cell surface and bind lymphocytes, and the binding can be partially inhibited
with anti–VAP-1 mAbs. VAP-1 has no similarity to any currently known adhesion molecules,
but has significant identity to the copper-containing amine oxidase family and has a monoamine
oxidase activity. We propose that VAP-1 is a novel type of adhesion molecule with dual func-
tion. With the appropriate glycosylation and in the correct inflammatory setting, its expression
on the lumenal endothelial cell surface allows it to mediate lymphocyte adhesion and to func-
tion as an adhesion receptor involved in lymphocyte recirculation. Its primary function in
other locations where it is expressed, such as smooth muscle, may depend on its inherent
monoamine oxidase activity.
Key words: vascular adhesion protein 1 • adhesion molecule • monoamine oxidase • 
sialoglycoprotein • endothelial
 
C
 
ontinuous recirculation of lymphocytes between
blood and tissue is critical for the functioning of the
immune system. The adhesive interactions between multi-
ple receptors on the circulating lymphocytes and their
ligands expressed on the surface of endothelial cells in post-
capillary venules provide both the means for the emigration
process and a way to selectively control it. Although con-
siderable progress has been made recently in describing the
cascade of events required for a circulating leukocyte to
pass into the tissue from freely flowing blood, much in this
process remains to be discovered.
Present hypotheses suggest a multistep model of leuko-
cyte adhesion to endothelium that relies on a cascade of se-
quential but overlapping molecular interactions between
several receptor–ligand pairs (1–3). The initial transient and
tethering interactions between a leukocyte in the blood
stream and the vessel wall are performed principally by the
selectins and their glycoprotein ligands (4–6). Integrins and
other molecules may also have a role in this phase (7). This
rolling and sampling step can, in the presence of the appro-
priate signals, be followed by firm adhesion mediated by
the binding of activated integrins to their Ig superfamily
ligands (4). Locally elevated levels of chemokines and other
chemoattractants might be involved in initiating this activa-
tion, which is mediated by the appropriate receptors and
subsequent transduction of signals within the cell (8–10).
The final stage involves the transmigration of the bound
cell through the endothelial lining into the tissue by mech-
anisms that are poorly understood. Tissue-specific recircu-
latory pathways, such as those of the gut and skin, rely on
the regulated expression of particular adhesion molecule
receptor–ligand pairs in the appropriate location (3).
We have described previously a murine mAb, 1B2, recog-
nizing vascular adhesion protein 1 (VAP-1),
 
1
 
 a novel human
 
1
 
Abbreviations used in this paper:
 
 BSAO, bovine serum amine oxidase;
CHO, Chinese hamster ovary; DAO, diamine oxidase; GCG, Genetics
Computer Group; HEV, high endothelial venule(s); MAO, monoamine
oxidase; PLN, peripheral lymph node(s); PNAd, PLN addressin; SSAO,
semicarbazide-sensitive amine oxidase; VAP-1, vascular adhesion protein 1.
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cell adhesion molecule prominently expressed in high endo-
thelial venules (HEV) of peripheral lymph nodes (PLN),
through which much lymphocyte recirculation takes place.
mAb 1B2 can block lymphocyte binding to tonsillar, synovial,
and PLN HEV in a frozen section assay as well as to purified
tonsillar VAP-1 (11–13). VAP-1 expression is upregulated on
the endothelial cell surface under inflammatory conditions in
nonlymphoid tissue such as the skin and synovium, suggesting
that the molecule can also mediate the increased lymphocyte
emigration found in inflamed tissue (12–14).
Two species of VAP-1 of differing molecular mass can
be detected by mAb 1B2 immunoprecipitation of tonsil tis-
sue, one of 90 and the other of 170–180 kD. However, af-
ter immunoblotting and detection with mAb 1B2 under
nonreducing conditions, only the 170–180 kD species is
detected (15). Immunoreactive VAP-1, with slightly differ-
ent molecular masses, can also be found in other locations,
particularly in the smooth muscle cells of the vasculature as
well as in other smooth muscle–containing tissues (refer-
ence 12, and our unpublished observations). Studies of ton-
sillar VAP-1 using digestion with specific glycosidases have
shown that VAP-1 is a sialoglycoprotein, probably contain-
ing both N- and O-linked sugars with abundant sialic acid
residues of both the 
 
a
 
2,3- and 
 
a
 
2,6-linked type. It has also
been shown that VAP-1 mediates lymphocyte binding to
HEV in lymphatic tissues under nonstatic conditions and in
a sialic acid–dependent manner, as the desialylated mole-
cule can no longer support lymphocyte binding in the fro-
zen section assay (15). In vivo, VAP-1 mediates the initial
interactions between lymphocytes and inflamed vessels
when analyzed by intravital microscopy (16). VAP-1 is dis-
tinct from the PLN addressin (PNAd) defined by the mAb
MECA-79, though both VAP-1 and PNAd can mediate lym-
phocyte binding to PLN under shear conditions. However,
in contrast to PNAd, VAP-1 can operate in an L-selectin–
independent manner and support the binding of both L-selec-
tin–negative and –positive lymphocytes (15, 16). There-
fore, VAP-1 is a molecule with an adhesive function in an
alternative pathway operating independently of L-selectin,
and is likely to mediate early interactions in lymphocyte
binding to PLN-type HEV and vessels in inflammatory foci.
To analyze this protein at the molecular level, we have iso-
lated a cDNA clone encoding it and show that VAP-1
defines a functional new adhesion molecule possessing a
monoamine oxidase (MAO) activity.
 
Materials and Methods
 
Abs and Reagents.
 
Mouse mAb 1B2 against VAP-1 and nega-
tive control mAb 3G6 and 7C7 against chicken antigens have
been described previously (11, 17). mAb TK8-14 against VAP-1
was produced by immunizing Balb/c mice with immunoaffinity-
purified VAP-1 (17a). TK8-14 detects both the monomeric and
dimeric forms of VAP-1, stains tissues in an identical manner to
mAb 1B2, and blocks lymphocyte adhesion to PLN HEV in the
Stamper-Woodruff frozen section assay. Its specificity was con-
firmed by a positive reaction with VAP-1 cDNA transfectants.
The mAb M2 recognizing the FLAG peptide was obtained from
KEBO Lab Oy (Espoo, Finland). Chemical reagents were from
Sigma Chemical Co. (St. Louis, MO).
 
VAP-1 Purification and Sequencing.
 
Normal gut samples ob-
tained from abdominal surgery were dissected free from the lam-
ina propria, minced into small pieces, and lysed in a lysis buffer
(150 mM NaCl, 10 mM Tris-base, pH 7.2, 1.5 mM MgCl
 
2
 
, 1%
NP-40, 1% aprotinin, and 1 mM PMSF) overnight. After clarifi-
cation, the lysate supernatant was applied sequentially to immu-
noaffinity columns containing 5 ml of CnBr-activated Sepharose
beads armed with normal rat serum, nonbinding mAbs, and an
anti–VAP-1 mAb (3 mg/ml beads). After washing with lysis
buffer, the VAP-1 antigens were eluted with 50 mM trieth-
ylamine, frozen, and subsequently lyophilized. The sample was
then dissolved in nonreducing Laemmli’s sample buffer and sepa-
rated on a 5–12.5% SDS-PAGE gel. After transfer to polyvinyl-
idine difluoride membrane (Applied Biosystems, Inc., Foster
City, CA) by electroblotting, the membrane was stained with
Coomassie blue, and the 90- and 170–180-kD bands were ex-
cised. The whole of the 170–180-kD band and a portion of the
90-kD material were subjected to NH
 
2
 
-terminal and tryptic pep-
tide sequencing (477A; Applied Biosystems, Inc.) as described
previously (18). Matrix-assisted laser desorption mass spectrome-
try (Lasermat; Finnigan Corp., San Jose, CA) was used to confirm
the predicted mass of some of the peptides.
 
Molecular Biology Techniques.
 
DNA cloning and manipulation
were performed according to standard techniques (19) or by us-
ing commercially available kits following instructions supplied by
the manufacturer. Plasmid DNA was sequenced using a Seque-
nase version 2.0 kit (US Biologicals, Cleveland, OH) or in the
DNA sequencing facility of the University of Turku, Department
of Medical Genetics. Sequence assembly and analysis were per-
formed using the Wisconsin Package version 8.1 UNIX of the
Genetics Computer Group (GCG, Madison, WI), and database
comparisons were made using the BLAST server of the National
Center for Biotechnology Information (http://www.ncbi.nlm.
nih.gov/). Oligonucleotide primers for sequencing and PCR were
obtained from KEBO Lab Oy. The primers used for amplifying
VAP-1 cDNA fragment from smooth muscle mRNA by reverse
transcription PCR were N2 (gctgtgatcacmatyttygc), designed from
the VAP-1 NH
 
2
 
-terminal protein sequence AVITIFA (residues
13–19 of the complete protein), and T4 (ccggccctgrtagaasac), de-
signed from the tryptic peptide sequence VFYQGR (residues
264–269). Amplification conditions with these primers were
94
 
8
 
C, 1 min; 55
 
8
 
C, 1 min; 72
 
8
 
C, 2 min for 30 cycles. Human
multiple tissue Northern blots were obtained from Clontech
(Palo Alto, CA) and hybridized with 
 
32
 
P-labeled probes as rec-
ommended by the manufacturer. The human cDNA library panel
and lung (HL3004a) and heart (HL3026a) cDNA libraries were
from Clontech.
 
Amine Oxidase Assays.
 
Confluent Chinese hamster ovary
(CHO) or Ax cells stably expressing VAP-1 (10–15 
 
3 
 
10
 
6
 
 per
flask) were detached with trypsin-EDTA, washed in culture me-
dium, and resuspended in 1.5 ml of lysis buffer. The lysate was
clarified by centrifugation and used directly in enzyme assays (10–
50 
 
m
 
l per assay). Total protein concentrations were measured by
the Bradford method using bovine gammaglobulin as a standard
and a protein assay kit (Bio-Rad Laboratories, Hercules, CA).
Amine oxidase activities were measured using a spectrophoto-
metric method exactly as described by Holt et al. (20) in a vol-
ume of 200 
 
m
 
l in 96-well plates, and the absorbance change was
monitored in a Victor multilabel plate counter at 490 nm (Wal-
lac, Turku, Finland). Substrate concentrations were 1 mM, and
samples were preincubated with amine oxidase inhibitors for 30 
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min before assay if required. All enzyme assays were performed in
the presence of blanks containing boiled (5 min, 100
 
8
 
C) or mock
sample in duplicate or triplicate. Tonsillar VAP-1 was purified us-
ing a Sepharose CNBr anti–VAP-1 mAb immunoaffinity column,
as described above, but was assayed directly without elution from
the beads. Controls of crude porcine kidney diamine oxidase
(DAO) and bovine plasma MAO were obtained from Sigma
Chemical Co. Detection of the quinone cofactor in purified VAP-1
was performed by the redox cycling method of Paz et al. (21).
 
Cell Culture and Expression of VAP-1 cDNAs in Mammalian
Cells.
 
COS-7 (monkey fibroblasts) and CHO cells obtained
from the American Type Culture Collection (Rockville, MD)
and Ax (rat HEV–derived) cells originating in the laboratory of
M. Miyasaka (Osaka University, Osaka, Japan; reference 22) and
obtained with his permission from R. Renkonen, University of
Helsinki (Helsinki, Finland), were used as hosts for transfection
and expression of VAP-1. COS-7 and CHO cells were grown ac-
cording to standard procedures. Ax cells were cultured as de-
scribed (22). Expression plasmids consisting of the VAP-1 cDNA
in pcDNA3 (Invitrogen Corp., San Diego, CA) were used for
transient COS-7 cell transfections and generation of stably trans-
fected CHO and Ax cell lines. Expression plasmids (20 
 
m
 
g) were
used to transfect cells by electroporation (0.3 kV, 960 
 
m
 
F,
0.4-cm cuvette in RPMI plus 1 mM Na-pyruvate, 2 mM
L-glutamine, without serum) or by the Lipofectamine method
(GIBCO BRL, Gaithersburg, MD) using 2 
 
m
 
g of DNA. Tran-
siently transfected cells were assayed 3 d after transfection. Stably
transfected cells were selected by culturing in the presence of 0.5
mg/ml Geneticin (GIBCO BRL) for 4 wk.
 
Immunomagnetic Selections.
 
Stably transfected Ax and CHO
cells were selected for uniformly brightly positive cells using mag-
netic activated cell sorting (MACS
 
Ò
 
; Miltenyi Biotec Inc., Au-
burn, CA). In brief, confluent monolayers of transfected cells
were detached by a brief trypsin-EDTA treatment. Thereafter,
the cells were incubated with a saturating concentration of anti–
VAP-1 mAb. After washing, the cells were incubated with anti–
mouse IgM–specific superparamagnetic microbeads (Miltenyi
Biotec Inc.) and subjected to positive selection in an AS type
MACS
 
Ò
 
 column according to the manufacturer’s instructions.
Positively selected cells eluted from the column were stained for
immunofluorescence using an FITC-labeled anti–VAP-1 mAb,
TK8-14, which detects a different epitope on VAP-1 than mAb
1B2. Most positive cell lines were chosen for further culture, and
the selection was repeated periodically to maintain high expres-
sion levels of the transfectants.
 
FACS
 
Ò
 
 Analyses.
 
Stably or transiently transfected cells were
detached from the culture flasks by a short trypsin-EDTA treat-
ment (identical results were obtained using EDTA only, which
indicates that brief trypsinization does not destroy VAP-1). After
washings, normal surface staining was done as described (15). For
detection of intracellular antigens, the cells were permeabilized by
a 2-min incubation in 
 
2
 
20
 
8
 
C acetone. The cells were then di-
luted immediately in an excess of the culturing medium and
washed twice. After blocking nonspecific binding by a 20-min
incubation on ice with an FCS-containing medium, the cells
were stained normally using indirect immunofluorescence stain-
ing. The cells were finally fixed in 1% paraformaldehyde, and 10
 
4
 
cells were analyzed using FACScan
 
Ò
 
 and Lysys II software (Bec-
ton Dickinson, Mountain View, CA). In all stainings, isotype-
matched nonreactive negative control mAbs were used to set the
level of nonspecific background staining.
 
Adhesion Assays.
 
Ax cells in which VAP-1 was stably ex-
pressed or mock control transfectants were plated within wax-
pen circles drawn on gelatin-precoated microscope slides (2 
 
3
 
10
 
4
 
 cells per 2-cm-diameter circle). The cells were allowed to
grow to confluence, and after two washings, 100 
 
m
 
l of RPMI
1640 medium containing 10% FCS and 10 mM Hepes (the assay
medium) was added within each wax-pen circle to evenly cover
the adherent cell monolayer. Meanwhile, PBL were isolated from
freshly drawn blood using Ficoll centrifugation and adjusted to a
concentration of 40 
 
3
 
 10
 
6
 
 cells/ml in the assay medium. There-
after, the slides were transferred to an orbital shaker operating at
60 rpm at 7
 
8
 
C, and 50 
 
m
 
l of the PBL suspension was applied onto
each wax-pen circle. The assay was continued for 30 min with
constant rotation. The slides were carefully decanted and dipped
once in cold RPMI to remove nonadherent cells. Adherent cells
were fixed to the sections by incubating the slides vertically in
ice-cold PBS containing 1% glutaraldehyde overnight. The num-
ber of adherent cells was counted using an ocular grid (magnifica-
tion 
 
3
 
200). The grid covers an area of 0.25 mm
 
2
 
. Nine pre-
defined areas of 0.25 mm
 
2
 
 at the center of the circle where the
transfectants formed a confluent monolayer were counted on
each slide. Two slides per sample (total area, 4.5 mm
 
2
 
) were
counted in each of five independent experiments. In certain ex-
periments, the adhesion assay was performed in the presence of
function-blocking mAbs against VAP-1 (a combination of 1B2
and TK8-14, both at 50 
 
m
 
g/ml diluted in the assay medium) or
class-matched negative control mAbs (a combination of 3G6 and
7C7, both at 50 
 
m
 
g/ml). The mAbs were preincubated with the
transfectant monolayer on the slides for 30 min at 7
 
8
 
C before the
labeled lymphocytes were added. The number of adherent cells
was counted in five independent experiments as described above.
 
Results
 
Isolation of a VAP-1 cDNA.
 
Human gut smooth mus-
cle, in which VAP-1 is strongly expressed, was obtained
from material removed in surgical procedures. Using an
mAb immunoaffinity column, the 90- and 170–180-kD
forms of VAP-1 were purified from detergent lysates of the
tissue in sufficient quantities to obtain internal peptide se-
quence after digestion with trypsin and V8 protease. In ad-
dition, a portion of the 90-kD VAP-1 was subjected to
NH
 
2
 
-terminal sequencing directly. The peptide elution
profile from the HPLC column used to purify the peptides
from both forms of VAP-1 was identical, as were the pep-
tide sequences of the corresponding peaks, indicating that
the protein is a homodimer composed of two 90-kD sub-
units. It should be noted that the NH
 
2
 
-terminal protein se-
quence is different from that reported previously for VAP-1
(11), which was later shown to be from an unrelated mouse
protein of identical size to VAP-1 that coprecipitated with
the mouse mAb used in the immunopurification (23).
VAP-1 peptide sequences were used to design partially
degenerate oligonucleotide primers for reverse transcrip-
tion PCR experiments on mRNA prepared from human
gut smooth muscle. A single cDNA fragment of 
 
z
 
700 bp
was amplified. The partial cDNA sequence contained a
continuous open reading frame that encoded a protein
containing some of the sequences of the tryptic and V8
peptides of the immunopurified VAP-1 material, thereby
confirming that the correct cDNA fragments had been am-
plified. A panel of 10 human cDNA libraries was analyzed 
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by PCR in order to identify those containing VAP-1 cDNAs,
and those giving the strongest signal were screened with
the PCR-generated VAP-1 cDNA fragment. In this man-
ner, a number of overlapping cDNA clones were isolated
from human lung and heart cDNA libraries. Two overlap-
ping lung cDNAs were sequenced completely on both
strands. The resulting combined cDNA was 2,501 bp in
length and contained a continuous open reading frame of
2,292 bp starting at an ATG methionine codon. This me-
thionine was followed by the peptide sequence found at
the NH
 
2
 
-terminal of the purified 90-kD VAP-1 protein,
and the contiguous open reading frame encoded all of the
VAP-1 tryptic and V8 peptides identified by protein se-
quencing (Fig. 1). A 5
 
9
 
 untranslated region of 80 bp and a
3
 
9
 
 untranslated region of 129 bp following the TAG stop
codon were present in the clone. Neither a polyadenyla-
tion signal nor a poly A sequence was found at the 3
 
9
 
 end
of the cDNA, suggesting that the native VAP-1 mRNA
may be longer than indicated by the cDNA isolated here.
 
Adhesion Assays.
 
The VAP-1 cDNA in pcDNA3 was
used to transfect Ax cells, a rat HEV–derived endothelial
cell line (22) that probably provides a more natural func-
tional environment for VAP-1 than other potential hosts
such as CHO cells. Stable transfectants were obtained
which expressed VAP-1 on their cell surface as determined
by FACS
 
Ò
 
 analysis (Fig. 2 
 
A
 
), and these were used in lym-
phocyte adhesion assays. When analyzed under rotatory
conditions, PBL bound to VAP-1–transfected Ax cells 25.6
times better than to mock-transfected cells (Fig. 2, 
 
B
 
 and
 
C
 
). The enhanced binding to VAP-1 transfectants was sta-
tistically significantly inhibited, although not abolished com-
pletely, by anti–VAP-1 mAb treatment (inhibition 29.6 
 
6
 
10.7%,
 
 P 
 
5 
 
0.05). These adhesion results are pooled from
five independent experiments in which two to three parallel
transfectant monolayers were analyzed each time using three
independently transfected cell lines and PBLs from six differ-
ent donors. Thus, these data show that the VAP-1 cDNA
encodes a functional adhesion molecule which is located on
the cell surface of transfected cells, and which when ex-
pressed in Ax cells, can directly mediate the binding of PBL.
 
The VAP-1 Protein.
 
The open reading frame in the VAP-
1 cDNA encoded a 763–amino acid protein of 84.6 kD (Fig.
1). Searching of the available protein sequence databases re-
vealed that VAP-1 has significant identity to the copper-
containing amine oxidase family (EC 1.4.3.6). This identity
varied from 24% for 
 
Escherichia coli
 
 Cu–MAO to 41–81%
for other mammalian members of this family. The highest
identity, 81%, was found with bovine serum amine oxidase
(BSAO), which exhibited significant conservation
throughout the entire length of the protein except for a
short region at the NH
 
2
 
-terminal end of the molecule. A
recently published partial sequence of a rat adipocyte amine
oxidase (24) had considerable sequence conservation (83.1%
over 320 amino acids), including the NH
 
2
 
-terminal region,
Figure 1. Sequence of the
VAP-1 cDNA isolated from a
human lung cDNA library and
the predicted sequence of VAP-1
protein. Boxes, The NH2-terminal,
tryptic and V8 peptides purified
and sequenced from immuno-
purified VAP-1 protein. An itali-
cized amino acid residue within
a boxed region indicates that no
amino acid could be assigned to
that cycle in the peptide sequenc-
ing. Arrowed and circled asparagines,
Potential  N-glycosylation sites;
arrowed squares, the putative
O-glycosylation sites. Shading,
The transmembrane domain be-
tween residues 5 and 27. Scale dia-
gram (bottom) indicates the location
of the transmembrane domain
(shown by the filled transmem-
brane domain (TMD) region). N
and O, The relative location of
the putative glycosylation sites
in the extracellular portion of
the molecule, to show N- and
O-linked sugar attachment sites,
respectively. Scale bar, 50 amino
acids. These sequence data have
been submitted to DDBJ/EMBL/
GenBank as accession no.
AF067406. 
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suggesting that this may be a rat homologue of VAP-1. A
multiple alignment of VAP-1 with other mammalian mem-
bers of the copper-containing amine oxidase family is shown
in Fig. 3. VAP-1 has no significant identity to any currently
known adhesion molecules, and contains none of the pro-
tein domains sometimes found within such proteins, al-
though we note the occurrence of an RGD motif between
residues 726 and 728. The functional significance with re-
gard to integrin binding, if any, of this commonly occur-
ring motif is unknown. The protein has six potential
 
N
 
-glycosylation sites and three putative 
 
O
 
-glycosylation
sites (determined using the 
 
O
 
-glycosylation site prediction
E-mail server at netoglyc@cbs.dtu.dk [25]) per monomer
(Fig. 1). Examination of the protein sequence revealed no
obvious areas with characteristics of membrane-spanning
domains except for a region of 23 predominantly hydro-
phobic amino acids at the very NH
 
2
 
-terminal end (residues
5–27) of the molecule, indicated in Fig. 1. This region
could be interpreted as either a cleavable secretion signal,
because it contained a potential cleavage site at position 19
as determined by the method of von Heijne (26), or a
transmembrane domain. The NH
 
2
 
-terminal protein se-
quence of the 90-kD VAP-1 protein showed that this hy-
drophobic region was not cleaved off in the material we
had purified, and was thus unlikely to function as a normal
cleavable signal sequence for secretion. In addition, the
charge characteristics of the residues flanking the hydro-
phobic region suggested that it could be the membrane-
spanning domain of a type II membrane protein (27) hav-
ing a cytoplasmic NH
 
2
 
 terminus and a COOH-terminal
extracellular domain. To determine if this hypothesis was
correct, we made VAP-1 cDNA expression constructs in
which a FLAG epitope (DYKDDDDK) recognized by
mAb M2 was placed in frame after the initiating methio-
nine codon on the side of the putative transmembrane do-
main predicted to be within the cytoplasm. This construct
and a control construct in which the VAP-1 cDNA was
placed in an inverse orientation in the vector were trans-
fected into COS-7 cells, and the transient expression of the
FLAG and VAP-1 epitopes, recognized by mAbs M2 and
1B2, respectively, was analyzed by FACS
 
Ò
 
 analysis of per-
meabilized and nonpermeabilized cells (Fig. 4). A positive
cell population with the anti-FLAG mAb M2 was seen
with permeabilized cells only (Fig. 4, row 
 
F
 
, column 
 
5
 
),
whereas a VAP-1–positive cell population was seen in both
permeabilized and nonpermeabilized cells (Fig. 4, rows 
 
C
 
and 
 
F
 
, column 
 
4
 
). Control transfected cells were negative
with both the anti-FLAG and anti–VAP-1 mAbs (Fig. 4,
rows 
 
A
 
 and D, columns 4 and 5). This shows that the
NH2-terminal FLAG epitope is located on the cytoplasmic
side of the cell membrane, the hydrophobic region spans
the lipid bilayer, and there is a large COOH-terminal ex-
tracellular domain recognized by the adhesion blocking
mAb 1B2. All the putative glycosylation sites are located in
the extracellular portion of the molecule.
To determine the size and glycosylation status of recom-
Figure 2. Ax cells transfected with the VAP-1 cDNA mediate lymphocyte adhesion. (A) Expression of VAP-1 on the cell surface of Ax cells stably
transfected with VAP-1 cDNA or mock control (neg. co). x-axis, Intensity of staining on a log scale; y-axis, relative number of cells. (B) Increased VAP-
1–dependent binding of lymphocytes to VAP-1 transfectants. Considerably more PBL (small round spheres on top of the monolayer, arrows) are bound to
the VAP-1 transfectants (left) than to mock transfectants (right). Phase–contrast micrographs, original magnification 3100. (C) Quantitation of the bind-
ing. Results of five independent experiments are presented as mean 6 SEM.22 VAP-1 Is a Novel Multifunctional Adhesion Molecule
binant VAP-1 transiently expressed in Ax cells, we immu-
noblotted SDS-PAGE–separated cell extracts of VAP-1
and mock-transfected cells with and without prior sialidase
digestion (Fig. 5) using mAb 1B2. Consistent with the size
of VAP-1 found in vivo, a band at 170–180 kD was de-
tected which increased to 180–190 kD upon sialidase treat-
ment. This indicates that recombinant VAP-1, like native
VAP-1, is a sialoglycoprotein, and that the reduction in the
net negative charge due to removal of the negatively
charged sialic acids causes a decrease in the mobility of
VAP-1 in SDS-PAGE. A similar effect upon sialidase treat-
ment has been observed with tonsillar VAP-1 (15).
VAP-1 Enzyme Activity. The finding that VAP-1 has
significant identity to the copper-containing amine oxidase
family led us to examine if VAP-1 possessed amine oxidase
activity. The copper-containing amine oxidases are distin-
guished by the presence of an unusual quinone cofactor,
enzyme-bound copper, and activity only against primary
polyamines or monoamines (28). Thus, they are distinct
from the FAD-containing intracellular (mitochondrial)
MAOs. A stable CHO cell line which expressed VAP-1 on
the cell surface (determined by FACSÒ analysis, results not
shown) was obtained by transfection of CHO cells with an
expression vector containing the VAP-1 cDNA. Lysates of
these cells were assayed for DAO activity using putrescine
as a substrate, or MAO activity using benzylamine as a sub-
strate. As positive controls, commercially available DAO
and MAO were assayed, and negative controls were pro-
vided by mock plasmid–transfected CHO cell lysates. The
results showed that the VAP-1–expressing cells had negligi-
ble activity towards putrescine, but significant activity was
detected using the MAO substrate benzylamine (Table 1).
Mock CHO cell lysates showed insignificant activity. In
Figure 3. Multiple alignment
of the mammalian members of
the copper amine oxidase family,
including VAP-1. Labels (left) re-
fer to the particular protein
aligned in each row: BSAO;
VAP-1; human placental di-
amine oxidase 1 (PDAO1); hu-
man placental diamine oxidase 2
(PDAO2); and rat DAO. Num-
bers, The first amino acid in each
row of the aligned proteins. Se-
quences were extracted from the
latest available database and
aligned using GCG Pileup. Resi-
dues having identity with VAP-1
were highlighted using GCG
Boxshade.
Figure 4. FACSÒ analysis of VAP-1–transfected COS-7 cells to deter-
mine the membrane orientation and cellular location of VAP-1. Diagram
(top) indicates the structure of the two VAP-1 expression plasmids used to
transfect the COS-7 cells. VAP-1, The native VAP-1 expression con-
struct; VAP-1 FLAG, the FLAG epitope–tagged VAP-1. The negative
control for mock transfections was provided by a construct in which
VAP-1 is in an inverse orientation in the expression vector. Column 1,
The expression construct used in the transfection; column 2, no perme-
abilization (perm., 2) or permeabilization (1) of the transfected cells; col-
umn 3, negative control mAb staining (neg. co.); column 4, anti–VAP-1
mAb 1B2 staining; column 5, anti-FLAG mAb M2 staining. Rows A–F,
The expression construct or mock control used in transfection and the re-
sulting staining pattern of the transfected cells. Arrows, The positively
staining cell population.23 Smith et al.
the presence of 100 mM semicarbazide and 10 mM hydrox-
ylamine, specific inhibitors of copper-containing MAOs
(28), VAP-1 in CHO cells had no activity against benzyl-
amine (Table 1). In addition, we demonstrated that adhe-
sion-competent VAP-1 expressed in Ax cells also possessed
MAO activity against benzylamine which was inhibitable
by semicarbazide and hydroxylamine (Table 1). The lower
specific activities found in Ax cells probably reflect lower
expression levels of VAP-1 in these cells. The semicarba-
zide-sensitive amine oxidase (SSAO) inhibitor hydroxylamine
had no influence on the ability of VAP-1–expressing Ax
cells to support lymphocyte binding in adhesion assays (re-
sults not shown), suggesting that the enzyme activity is not
required for the adhesive properties of VAP-1 in these
cells. Ax cells themselves appear to possess a native MAO
activity against benzylamine which is not inhibitable by
semicarbazide or hydroxylamine, as a low level of activity
was detected in mock control cells (Table 1). To confirm
that MAO activity is found in VAP-1 in vivo, we immu-
noaffinity-purified VAP-1 from tonsil and assayed the material
in triplicate. Tonsillar VAP-1, like VAP-1 from transfected
CHO cells, demonstrated activity against benzylamine with
an A490 increase per hour of 0.09 at 378C under the assay
conditions used, which was 4.5 times greater than that of
boiled sample. It was not possible to measure specific activ-
ities due to the very low yield of tonsillar VAP-1 protein
obtained.
Benzylamine, although commonly used as a substrate for
measuring amine oxidase activity, is not found in vivo.
Thus, several biologically occurring endogenous amines
were tested to see whether they could be used by VAP-1
(Table 2). Methylamine at 1 mM appeared to be readily
used by VAP-1; however, no other amines tested demon-
strated reactivity. The lower specific activities observed
with benzylamine in these cell lysates compared with the
lysates assayed in Table 1 reflects the variation in VAP-1
expression found in different batches of cells.
The presence of a quinone cofactor in VAP-1 was
shown by separating a portion of the immunopurified ton-
sillar VAP-1 material by SDS-PAGE under reducing con-
ditions and transferring the material to nitrocellulose. The
nitrocellulose filter was then stained with nitroblue tetrazo-
lium/Na-glycinate under redox cycling conditions to spe-
cifically stain quinone moieties in the protein (21). The
stain reacted with both monomeric 90-kD and dimeric
170–180-kD VAP-1, showing that tonsillar VAP-1 proba-
bly has a quinone cofactor in each subunit (Fig. 6).
VAP-1 Expression. Northern blot analysis of mRNA
isolated from human gut smooth muscle and lymphocyte-
depleted tonsil stroma showed that the cloned VAP-1
cDNA hybridizes to a 4.1-kb mRNA in both tissues (Fig. 7
A). Further Northern blot analysis showed that a 4.1-kb
VAP-1 mRNA is expressed in a wide range of human tis-
Figure 5. Sialidase treatment of VAP-1 expressed in Ax cells. Cell ly-
sates from VAP-1–transfected and mock-transfected Ax cells were treated
with sialidase (1) or not (2) before SDS-PAGE, immunoblotting, and
probing with the anti–VAP-1 mAb 1B2 (lanes 1–4) or negative control
3G6 mAb (neg. co, lanes 5–8).
Table 1. Assay of Amine Oxidase Activity in CHO and Ax Cells Expressing VAP-1
Substrate
Cell type enzyme activity
CHO VAP-1 CHO mock DAO MAO Ax VAP-1 Ax mock
nmol product min21 mg21 protein
Putrescine 0.87 6 0.17 1.45 6 0.13 4.87 6 0.10 0.29 6 0.00 ND ND
Benzylamine 26.94 6 0.70 0.13 6 0.13 0.57 6 0.10 8.83 6 0.00 2.15 6 0.04 0.80 6 0.80
Benzylamine 1 SC* 0.61 6 0.17 1.32 6 0.26 ND ND 0.35 6 0.09 1.00 6 0.00
Benzylamine 1 HA‡ 0.35 6 0.17 1.32 6 0.26 ND ND 0.31 6 0.04 0.90 6 0.10
VAP-1 cDNA–transfected CHO and Ax cells or mock-transfected cells were assayed for amine oxidase activity using putrescine as a polyamine sub-
strate and benzylamine as a monoamine substrate, which was also assayed in the presence of MAO inhibitors. The experiment was performed at least
twice on different samples with comparable results, and the results of one representative experiment are shown. Each assay was done in triplicate, and
the mean specific activity 6 SEM is shown.
*Semicarbazide (SC) was at 100 mM.
‡Hydroxylamine (HA) was at 10 mM.24 VAP-1 Is a Novel Multifunctional Adhesion Molecule
sues. The message was not detectable in peripheral blood
leukocytes or brain but was strongly expressed in lung,
small intestine, and appendix compared with other tissues.
Only low amounts of the VAP-1 mRNA were detected in
spleen, thymus, testis, liver, pancreas, kidney, bone mar-
row, and fetal liver. An intermediate level of expression
was seen in prostate, ovary, the mucosal lining of the co-
lon, heart, placenta, skeletal muscle, and lymph node (Fig.
7 B). No other mRNA species of different size were de-
tected even after prolonged autoradiography.
Discussion
Prominent staining with the mAb 1B2 recognizing
VAP-1 is found on the endothelial cells of vessels in several
locations, particularly in PLN-type lymphoid tissues. How-
ever, as the total levels of VAP-1 found at these locations
are relatively low, it proved difficult to isolate and purify
sufficient quantities of endothelial VAP-1 from which to
obtain protein sequence information. Of the other tissues
in which VAP-1 is found, it is most abundant in the smooth
muscle of the vasculature and gut-associated smooth mus-
cle (12). VAP-1 from these sources has a marginally differ-
ent molecular mass, probably due to glycosylation differ-
ences, but otherwise resembles the form analyzed previously
in tonsil and other PLN-type tissues (our unpublished ob-
servations).
Using protein sequence information obtained from
VAP-1 purified from gut smooth muscle, we isolated a
cDNA encoding this adhesion molecule. Our evidence for
this is based on the following. First, protein sequence ob-
tained from immunopurified VAP-1 was found in the pre-
dicted protein sequence of the VAP-1 cDNA clone subse-
quently isolated. Second, transfected cells expressing the
VAP-1 cDNA could be stained on their surface with the
mAb 1B2 used originally to define VAP-1 (11), and VAP-1
immunoprecipitated from these cells had a similar molecu-
lar mass, 170–180 kD, to that found in vivo (15). Third,
VAP-1 cDNA–transfected Ax cells could support the ad-
herence of PBL, and this binding could be partially inhib-
ited by anti–VAP-1 mAb, showing that the cDNA encodes
a functional adhesion molecule. There is no conclusive ev-
idence to suggest that there are forms of VAP-1 encoded
by variant mRNAs. Thus, it seems likely that we have iso-
lated a cDNA encoding the predominant form of VAP-1
protein studied previously by immunoblotting and immu-
noprecipitation.
After the completion of this work, a human MAO
cDNA with an identical sequence to the VAP-1 cDNA
was described recently (29). However, no functional data
on the protein, its enzyme activity, or expression were pre-
sented by the authors, who concluded erroneously that the
cDNA sequence encodes a secreted rather than a trans-
membrane protein. Thus, the VAP-1 cDNA isolated here
is the first shown to encode a human membrane–bound
protein of the copper-containing amine oxidase family.
VAP-1 is a large, dimeric, type II transmembrane protein
having a membrane-spanning domain located at the NH2-
terminal end of the molecule. The intracellular domain is
particularly small, only four amino acids in length, leaving a
large glycosylated extracellular domain of some 163 kD per
dimer. All the potential glycosylation sites, 12 N-linked
and 6 putative O-linked per dimer, are located in the ex-
tracellular domain. Although it is not currently known if all
of these are used, previous data suggest that VAP-1 con-
tains both N- and O-linked sugars and numerous sialic acid
residues which are thought to play an important part in the
adhesive function of VAP-1 protein (15). The correct post-
translational processing of VAP-1 may be critical for its ad-
hesive function, as VAP-1 expressed in nonendothelial-
derived cell lines such as CHO and COS cells was unable
to support lymphocyte binding (results not shown). It may
be that only endothelial cells, such as the Ax host cells used,
contain the necessary precursors and express the essential
glycosyltransferases for the correct oligosaccharide modifi-
cations required for VAP-1 adhesive function. The critical
role of proper oligosaccharide modification for adhesion
Table 2. Substrate Specificity of VAP-1 Amine Oxidase Activity
Substrate
Cell type enzyme activity
CHO VAP-1 CHO mock
nmol product min21 mg21 protein
Benzylamine 4.57 6 0.29 0.18 6 0.62
Methylamine 4.28 6 0.22 0.18 6 0.44
Tyramine 0.04 6 0.10 0.09 6 0.35
Tryptamine 0.07 6 0.04 0.35 6 0.62
b-Phenylethylamine 0.10 6 0.03 0.26 6 0.00
Histamine 0.05 6 0.03 0.20 6 0.00
VAP-1 amine oxidase activity was measured in VAP-1 cDNA– and
mock-transfected CHO cell lysates using different substrates. The ex-
periment was performed twice on different samples with comparable
results, and the results of one representative experiment are shown.
Each assay was done in triplicate, and the mean specific activity 6 SEM
is given. Note that the activities cannot be directly compared with
those in Table 1 because the cells are from different batches and there-
fore do not have the same level of VAP-1 expression.
Figure 6. VAP-1 contains a quinone. Immu-
nopurified tonsillar VAP-1 was separated by SDS-
PAGE under reducing conditions and transferred to
a nitrocellulose filter. The filter was stained with ni-
troblue tetrazolium, which results in a blue/purple
staining of the filter at locations where quinones are
present, as described in Materials and Methods.
Two quinone-positive proteins are seen at 90 and
180 kD, corresponding to the size of tonsillar VAP-1
found in reducing conditions. The specificity of the
reaction can be seen by the blockage of background
staining of the nitrocellulose where other copurify-
ing proteins are present but which do not give a
quinone-positive reaction.25 Smith et al.
has been documented with other adhesion molecules such
as E-selectin ligand 1 and P-selectin glycoprotein ligand 1
(30, 31).
The adhesion assays performed on VAP-1–expressing Ax
cells indicated that the cDNA encodes a functional VAP-1
that can support interactions with its ligand on PBL and
lead to stable binding of the PBL to the Ax cells. However,
complete inhibition of this increased adhesion with anti–
VAP-1 mAbs 1B2 and TK8-14 was not observed, suggest-
ing that the VAP-1 molecule in rat-derived Ax cells is not
functioning exactly as it does in its native environment. It
may be that the carbohydrate modifications of the protein
in Ax cells, the local membrane environment, or VAP-1
conformation are sufficiently different from that in human
HEV such that the mAb can no longer block all VAP-1 in-
teractions with its ligand. It is also possible that a subpopu-
lation of VAP-1 molecules may exist on transfectants in a
form lacking one or other of the epitopes recognized by
mAbs 1B2 and TK8-14. Finally, we are left with the possi-
bility that long-term overexpression of VAP-1 in stable
transfectants alters the expression of other adhesion mole-
cule(s) on the Ax cell surface. Of course, the function of
this other putative adhesion molecule would not be inhib-
itable by anti–VAP-1 mAb. In HEV binding assays, VAP-1
has been shown to function independently of lymphocyte
L-selectin, and it mediates the binding of CD81 PBL much
better than CD41 PBL (16). Ax VAP-1 cDNA transfec-
tants reproduce these observations, since analysis of immu-
nomagnetically purified L-selectin–negative cells and CD81
and CD41 cells showed that L-selectin was not necessary
for efficient binding to Ax transfectants, and that the CD81
subset of PBL adhered severalfold better to VAP-1 trans-
fectants than CD41 cells (data not shown).
The intriguing finding that VAP-1 possesses an MAO
activity suggests that the protein may have multiple physio-
logical roles. In previous studies, we have clearly shown
that VAP-1 is an inducible adhesion molecule mediating
lymphocyte binding to PLN HEV as well as vessels in in-
flamed areas found in several inflammatory diseases (11, 12,
14–16). The expression of VAP-1 at these sites can help
mediate and regulate lymphocyte extravasation, and this
activity may be independent of the enzyme activity. In
other tissues where VAP-1 is expressed, such as smooth
muscle, its MAO activity may be its primary function.
Whether the two activities are linked is unclear at present,
but one can envisage that regulating amine levels could be
of importance in inflamed tissue, where there may be accu-
mulations of potentially toxic cellular amine metabolites
liberated from cells damaged as a result of the inflammatory
response. Another alternative is that the MAO activity may
be involved in regulating the levels of a bioactive amine
with a role in lymphocyte homing or inflammation.
We have shown that VAP-1 belongs to the widely dis-
tributed copper-containing amine oxidase family (28, 32)
and that the extracellular domain of VAP-1 contains this
activity. Thus VAP-1 is an ectoenzyme. A particular char-
acteristic of these enzymes is the presence of an unusual
carbonyl-containing topaquinone cofactor (33). In several
mammalian species, including humans, a copper-contain-
ing MAO found both in the cell membrane and in a solu-
ble form in serum has been identified (34–36). This activity
is sensitive to inhibition by carbonyl-reactive agents such as
semicarbazide and hydroxylamine, and the enzyme respon-
sible is commonly referred to as an SSAO (28). We have
shown that VAP-1 contains a covalently bound quinone,
and these results, as well as the sensitivity of VAP-1 enzyme
activity to the carbonyl-reactive agents semicarbazide and
hydroxylamine, show that VAP-1 is a membrane-bound
SSAO. It seems plausible that it is the same as the human
membrane-bound SSAO described previously by bio-
chemical studies and which has been reported to be ex-
pressed extensively in the vasculature, particularly in smooth
muscle, although it has also been found in other cell types,
including endothelial cells (28, 37). The physiological roles
of SSAOs have been difficult to define, since little is known
of their in vivo substrates, and since their substrate specific-
Figure 7. VAP-1 has a widely expressed 4.1-kb mRNA. (A) Northern blot analysis of VAP-1 mRNA in poly A1 RNA extracted from human gut
smooth muscle and tonsil stroma from which lymphocytes have been partially removed by washing and squeezing. A 4.1-kb hybridizing mRNA can be
seen in both lanes. (B) Northern blot analysis of VAP-1 mRNA in different human tissues. Northern blots were obtained from Clontech, and equal
amounts of mRNA are loaded in each lane. All the filters were probed with a 32P-labeled VAP-1 cDNA probe containing the entire coding sequence and
washed at high stringency (posthybridization washing conditions were 0.13 SSC, 0.1% SDS at 658C twice for 45 min).26 VAP-1 Is a Novel Multifunctional Adhesion Molecule
ities vary considerably between species. We have shown
that VAP-1 can use endogenously occurring methylamine
as substrate but not several other endogenous amines such
as tyramine, tryptamine, b-phenylethylamine, histamine, or
putrescine. Identification of other substrates used by VAP-1
may provide a useful insight into the role of the amine oxi-
dase activity.
VAP-1 would appear to belong to a growing family of
adhesion molecules that have an intrinsic enzymic or other
activity in addition to their adhesive ability. Such proteins
include lymphocyte CD38 (38), CD73 (18), the E-selectin
ligand ESL-1 (31), and heparanase (39).
The nature of the VAP-1 ligand is unknown at present.
However, the previously reported finding that sialic acids
are important for the adhesive ability of VAP-1 in sialidase-
treated tonsil sections suggests that a ligand–carbohydrate
interaction is important, at least for part of the adhesive
mechanism. As this does not involve any of the known se-
lectins, it is possible that another lectin-like molecule may
well be a VAP-1 ligand. The isolation of a VAP-1 cDNA
will facilitate studies to isolate the ligand and define further
the role that this unusual and multifunctional new adhesion
molecule plays in lymphocyte trafficking.
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